AMENDMENTS TO THE CLAIMS

Please amend claims 1-9 and 12-18 and cancel claims 19, 22-29, 31-35, 41, 42, and 44 without prejudice or disclaimer. This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A method of treating asthma in a subject comprising administering ~~an anti-C5 antibody~~ to a subject susceptible to or having asthma an anti-C5 antibody in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.

2. (Currently amended) A method of preventing asthma attacks comprising prophylactically administering ~~an anti-C5 antibody~~ to a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms an anti-C5 antibody in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.

3. (Currently amended) A method of reducing the severity of an asthma attack comprising administering ~~an anti-C5 antibody~~ to a subject having an asthma attack an anti-C5 antibody in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.

4. (Currently amended) A method of reducing airway obstruction in a subject comprising administering ~~an anti-C5 antibody~~ to the subject an anti-C5 antibody in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.

5. (Currently amended) A method of increasing air flow in a subject comprising administering ~~an anti-C5 antibody~~ to the subject an anti-C5 antibody in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.

6. (Currently amended) A method of reducing bronchial spasms in a subject comprising administering ~~an anti-C5 antibody~~ to the subject an anti-C5 antibody in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.

7. (Currently amended) A method of treating a chronic obstructive pulmonary disease in a subject comprising administering ~~an anti-C5 antibody~~ to the subject afflicted with a chronic obstructive pulmonary disease an anti-C5 antibody in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors,

PDE inhibitors, CD23 antagonists, IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.

8. (Currently amended) A method of reducing inflammation in a subject comprising administering ~~an anti-C5 antibody~~ to a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms an anti-C5 antibody in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.

9. (Currently amended) A method of treating a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms comprising administering an effective bronchial-dilating amount of an anti-C5 antibody in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.

10. (Original) A method as in claim 8 or 9 wherein the step of administering comprises administering the anti-C5 antibody during an asthma attack.

11. (Original) A method as in any of claims 1-9 wherein the subject is a human.

12. (Currently amended) A method as in any of claims 1-9, wherein the ~~step of administering an anti-C5 antibody comprises administering an~~ anti-C5 antibody ~~that~~ inhibits the conversion of complement component C5 into C5a and C5b.

13. (Currently amended) A method as in any of claims 1-9, wherein the ~~step of administering an anti-C5 antibody comprises administering an~~ anti-C5 antibody ~~that~~ binds to human complement component C5a.

14. (Currently amended) A method as in any of claims 1-9, wherein the ~~step of administering an anti-C5 antibody comprises administering an~~ anti-C5 antibody ~~that~~ binds to human complement component C5b-9.

15. (Currently amended) A method as in any of claims 1-9, wherein the ~~step of administering an anti-C5 antibody comprises administering an~~ anti-C5 antibody is selected from the group consisting of h5G1.1, h5G1.1-scFv and functional fragments of h5G1.1.

16. (Currently amended) A method as in any of claims 1-9, wherein ~~the step of administering an anti-C5 antibody comprises administering an anti-C5 antibody that is an~~ the anti-C5 antibody ~~comprising~~ comprises at least one antibody-antigen binding site, said antibody exhibiting specific binding to the alpha chain of human complement component C5, wherein the antibody 1) inhibits complement activation in a human body fluid; and 2) inhibits the binding of purified human complement component C5 to C5 convertase.

17. (Currently amended) A method as in any of claims 1-9, wherein the ~~step of administering an anti-C5 antibody comprises administering an~~ anti-C5 antibody is administered as an aerosol.

18. (Currently amended) A method as in any of claims 1-9, wherein the ~~step of administering an anti-C5 antibody comprises administering an~~ anti-C5 antibody is administered via a method selected from the group consisting of intravenous infusion by injection and subcutaneous injection.

19. (Cancelled).

20. (Previously presented) A method for treating a subject having or susceptible to asthma comprising administering at least one member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL4 antibodies, anti-IL-5 antibodies, β2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, IL 13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors in combination with an anti-C5 antibody.

21. (Original) A method of treating asthma comprising administering an anti-C5 antibody to the lungs of a subject without substantially reducing systemic complement activity in the subject.

22-44. (Cancelled).

45. (Previously presented) The method of claim 1, wherein the anti-C5 antibody is administered by nebulization.

46. (Previously presented) The method of claim 2, wherein the anti-C5 antibody is administered by nebulization.

47. (Previously presented) The method of claim 7, wherein the anti-C5 antibody is administered by nebulization.

48. (Previously presented) The method of claim 8, wherein the anti-C5 antibody is administered by nebulization.

49. (Previously presented) The method of claim 20, wherein the anti-C5 antibody is administered by nebulization.

50. (Previously presented) The method of claim 20, wherein the selected member is administered by nebulization.